Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Marker Therapeutics, Inc.MRKR · Entity 7609 | Director | May 24, 2022 | May 26, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Marker Therapeutics, Inc.
Report date May 24, 2022 · Filed May 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2032-05-23 | Direct | 80,000 |
Reported balance
After 2022-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-24 · Grant · Acquired 80,000 · Balance 80,000 F1: This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2022 Filed May 26, 2022 20:10 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001209191-22-032175 · doc4.xml · derivative · entry 1 Laskow-Pooley David · CIK 0001638533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-05-23 F1 · derivative.exercise_date: This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 22:56 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantCommon Stock | 12,658 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039634 · doc4.xml · nonDerivative · entry 1 Laskow-Pooley David · CIK 0001638533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,223 F1 · shares: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting. Read SEC document |
| May 19, 2020 Filed Feb 12, 2021 22:13 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantCommon Stock | 17,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010231 · doc5.xml · nonDerivative · entry 1 Laskow-Pooley David · CIK 0001638533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,565 F1 · shares: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately preceding the date of the Company's 2019 annual meeting. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:01 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantCommon Stock | 7,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-025605 · tv521407_4.xml · nonDerivative · entry 1 Laskow-Pooley David · CIK 0001638533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,543 F1 · shares: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $5.51 per share, on the day immediately preceding the date of the Company's 2019 annual meeting. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 12:48 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 5,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-054103 · tv504933_4.xml · nonDerivative · entry 1 Laskow-Pooley David · CIK 0001638533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,283 F1 · shares: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 20:03 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 13,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-045905 · v474357_4.xml · nonDerivative · entry 1 Laskow-Pooley David · CIK 0001638533 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,115 F1 · shares: Represents the portion of the annual retainer for each non-employee director payable in immediately vested restricted, common stock under the Company's 2014 Omnibus Stock Ownership Plan and based on the closing price of $3.05 per share, on the day immediately preceding the date of the Company's 2017 annual meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.